NEW YORK (GenomeWeb News) – Protein biomarker company Peakadilly today said it has raised €8.5 million ($10.9 million) in the second and final round of its series A financing.
Peakadilly said it will use the cash to increase the capacity of its protein biomarker-discovery operation, which is based on its MASStermind technology.
It will also enable it to “accelerate development of its own diagnostic and pharmacodiagnostic products,” the firm said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.